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e-mail address: drgsunil@yahoo.com (S. Ganekal).Sunil Ganekal, FRCS a,⇑; Syril Dorairaj, MD bAbstractPurpose: To evaluate the efficacy of a combination of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) during
vitrectomy, as adjuvants in preventing proliferative vitreoretinopathy (PVR).
Design: Double-blind, prospective, randomized placebo-controlled trial.
Methods: Forty consecutive patients diagnosed with rhegmatogenous retinal detachment with high-risk PVR, were randomized to
study and control groups (n = 20 each). Study group (group 1) patients underwent vitrectomy with the use of both intraoperative 5-
FU (0.2 mg/ml) and LMWH (5 IU/ml). In the control group (group 2), a similar surgery was performed without the use of adjuvants.
Patients were evaluated at 1 month, 3 months and 6 months after surgery. Postoperative retinal reattachment, recurrence of PVR,
best-corrected visual acuity and complications at the end of 6 months were compared between the two groups. A Chi-square
statistical analysis was used on all of the outcome measures.
Results: At 6 months post-surgery, 62.5% of patients had reattached retina. There was no significant difference (Chi-square test
showed x2 = 0.106, P = 0.7447, P > 0.05) in retinal reattachment in both of the groups. The rate of postoperative PVR in the control
group was 55%; in the study group, the rate was 45% (the Chi-square test showed x2 = 0.4, P = 0.5271, P > 0.05), which proves
statistically insignificant. In addition, there was no statistically significant difference in visual outcomes between the two groups
(Chi-square test showed x2 = 0.1002, P > 0.05), no significant difference in the complication rate and drug toxicity was noted
between two groups.
Conclusions: This study fails to prove the efficacy of the intraoperative use of 5-FU and LMWH in combination as an antiprolifer-
ative regiment for the prevention of postoperative PVR or improvement in final visual acuity. At the same time, no significant
complications could be attributed to the treatment.
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PVR is an anomalous scarring process of the detached ret-
ina due to the growth and contraction of cellular membranes
within the vitreous cavity and on both sides of the retinalsurface. Despite improvements in the primary success rate
of retinal detachment surgery,1 PVR remains the most
common cause of failure, with a reported incidence of 5.1–
11.7%.2–8 PVR is responsible for the failure of more than
75% of cases in retinal detachment surgery.9–11 Althoughe:
al.com
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anatomical success rate of surgery, multiple surgical interven-
tions are often necessary to treat PVR, and final visual results
are often disappointing, with visual prognosis remaining
poor.12–15 An improved understanding of the pathophysiol-
ogy of PVR has led to the use of adjunctive therapies to
prevent PVR, simplify its surgical management and improve
outcomes. Low molecular weight Heparin has been shown
to reduce postoperative fibrin after vitrectomy.16 Heparin
binds to fibronectin and to a wide range of growth factors,
including acidic and basic fibroblast growth factors and
platelet derived growth factors.17 5-FU inhibits DNA synthe-
sis, inhibits fibroblast proliferation and has been effective in
reducing rates of PVR in animal models.18 The actions of 5-
FU and LMWH occur at different stages of the PVR process,
and using these agents in conjunction may produce a syner-
gistic effect.
In a randomized controlled study of high-risk retinal
detachment cases, identified using a risk assessment
algorithm,19–20 adjunctive therapy with 5FU and LMWH de-
creased the incidence of PVR from 26.4% in the control group
to 12.6% in the treatment group.21 Conversely, a further
study of patients with established PVR using the aforemen-
tioned adjunctive combination, showed no significant
treatment effect.22 These varied results emphasize the impor-
tance of developing treatments aimed at well-defined clinical
subgroups of PVR development.
We report the results of a further randomized prospective
study on adjunctive 5-FU and LMWH, undertaken to
determine the efficacy of this combination in improving the
outcome of surgery for established high-risk PVR. The use
of adjunctive medication was aimed at preventing reprolifer-
ation and, thereby, reducing the number of reoperations and
potentially improving the visual outcome of surgery.Materials and methods
Forty eyes of 40 consecutive patients with PVR who
underwent vitrectomy for retinal detachment (RD) between
January 2009 and April 2010 were enrolled in the study.
The study was approved by local research ethics commit-
tee. Patients were randomly divided into 2 groups: 20 pa-
tients in the study group (group 1) and 20 patients in the
control group (group 2). In group 1, all 20 patients underwent
surgery for PVR with the use of intraoperative 5-FU and
LMWH. In group 2, a similar surgery was performed on all
20 patients without the use of 5-FU or LMWH.
Inclusion criteria for the study required all patients with
rhegmatogenous retinal detachment with high risk PVR to
have a minimum follow-up of 3 months. An updated classifi-
cation of retinal detachment with PVR by the Retina Society
Terminology Committee was used to classify preoperative
PVR.23 A preoperative scoring system for high risk PVR was
used, as described by Asaria et.al. [PVR scor-
e = 2.88  (Grade C PVR) + 1.85  (Grade B PVR) + 2.92 
(aphakia) + 1.77  (anterior uveitis) + 1.23  (quadrants of
detachment) + 0.83  (vitreous hemorrhage) + 23  (previ-
ous cryotherapy)].19 If the total score was >6.33, the patient
was considered at high risk for PVR and was included in the
study for randomization.
Patients with proliferative diabetic retinopathy, bleeding
diathesis, hepatic and renal failure, glaucoma, giant retinaltear, posterior penetrating trauma, corneal opacity sufficient
to impair surgical view, no light perception vision, inability to
give informed consent, inability to complete follow-up, and
unwillingness to accept randomization were excluded from
the study.
At the time of recruitment, patients were given an infor-
mation sheet with a complete and thorough explanation of
the trial. Upon recruitment, details of medical and ophthal-
mic examinations were recorded. Data collected at the pre-
operative clinical assessment included best-corrected visual
acuity, refractive status, intraocular pressure (IOP) (mmHg),
corneal clarity, presence of anterior segment inflammation,
lens status, presence of vitreous hemorrhage, number of ret-
inal breaks, and extent of retinal detachment (recorded in
clock hours). Vitreous hemorrhage was recorded as
present if a hemorrhage was observed in the vitreous base,
vitreous gel, or on the retinal surface. On the day of surgery,
non-trial personnel randomized recruited patients to the
group 1 and group 2 using a computer-generated weighted
coin method.
The basic steps of surgery were same for both the groups
and all surgeries were performed by a single surgeon (SG).
For young and uncooperative patients, general anesthesia
was used; for adults, peribulbar anesthesia along with mild
anxiolytics was used. A standard 3-port pars plana vitrectomy
was performed, along with lensectomy for lens opacity or the
management of anterior PVR. Elimination of traction suffi-
cient to allow retinal reattachment was achieved by epiretinal
membrane peeling or relaxing retinotomy and retinectomy.
Retinopexy was applied to treat retinal breaks using endola-
ser and/or cryotherapy. A scleral buckle or encircling band
was used in relevant cases. 6 o’clock iridotomy was done
for aphakic siliconized eyes. Air, perflouropropane (C3F8)
gas and silicone oil were used for internal tamponade. Post-
operative prone positioning was advised in all the patients.
In patients allocated to the group 1, intraoperative 5-FU
(0.2 mg/ml) and LMWH (5 IU/ml) were added to the infusion
fluid (100 mg of 5-FU and 2500 units of LMWH in 500 ml bot-
tle), while a normal saline placebo was added to the fluid of
group 2 patients. In cases lasting for more than one hour, the
infusion bag was replaced with a new, identical infusion. After
surgery, clinical data were recorded at 1 month, 3 months
and 6 months. Patient characteristics for the treatment
groups were tabulated to check for any major dissimilarity
at baseline. Postoperatively both the groups were compared
for best corrected visual acuity, retinal reattachment,
recurrence of PVR, need for additional operations and
complications.
Results
Mean age of the patients was 28.5 ± 6.8 years in group 1
and 38.5 ± 7.2 years in group 2. Majority of the patients were
males in group 1 (n = 18) as well as in group 2 (n = 13). Eight
percent of the patients in group 1 and 75% of the patients in
group 2 had previously undergone an intraocular surgery
(Fig. 1). Risk factors for the development of recurrent PVR
in both groups are shown in Table 1. Table 2 shows the
details of the surgical procedures performed in both groups.
Secondary vitrectomy was performed for failed sclera buck-
ling and a repeat vitrectomy was performed for recurrent
retinal detachments. Silicone oil (group 1, n = 16; group 2,
n = 12), C3F8 gas (group 1, n = 1; group 2, n = 2) and air
Figure 1. Bar diagram showing the details of previous surgeries
performed in patients recruited (Cat Ext-cataract extraction without
intraocular lens, IOL-intraocular lens implantation, SB-scleral buckle,
V-vitrectomy, SB + V-scleral buckle + vitrectomy).
Table 1. Risk factors for recurrent PVR in study (group 1) and control
(group 2) groups.
Risk factor for
recurrent PVR
Group 1 (No. of
patients)
Group 2 (No. of
patients)
Grade B PVR 6 (30%) 5 (25%)
Grade C PVR 14 (70%) 12 (60%)
Surgical aphakia 8 (40%) 6 (30%)
RD in all 4 quadrants 17 (85%) 18 (90%)
Anterior uveitis 3 (15%) 6 (30%)
Vitreous hemorrhage 4 (20%) 2 (10%)
Previous cryotherapy 4 (20%) 7 (35%)
Table 2. Details of surgery in study and control groups.
RD surgery details Group 1 (No. of
patients)
Group 2 (No. of
patients)
Primary vitrectomy 9 (45%) 9 (45%)
Secondary
vitrectomy
3 (15%) 3 (15%)
Repeat vitrectomy 8 (40%) 8 (40%)
Retinectomy 4 (20%) 3 (15%)
Lensectomy 5 (25%) 3 (15%)
Phacoemulsification 0 3 (15%)
IOL explanation 1 (5%) 0
Figure 2. Bar diagram showing treatment-related complications
observed in study and control groups.
5 FU and LMWH in the management of high risk PVR 259(group 1, n = 3; group 2, n = 6) were used for intraocular tam-
ponade in both groups.
Main complications encountered were intraoperative
bleeding, raised intraocular pressure, annular synechiae and
band shaped keratopathy (Fig. 2). At the end of 6 months
25 (62.5%) patients had reattached retina [13 (65%) in group
1 and 12 (60%) in group 2]. Of the13 patients with attached
retina in group 1, one patient showed evidence of early
PVR inferiorly and 1 patient had retinal detachment beyond
the lasered retina. Both these patients had useful visual
acuity.
Partial retinal detachment was seen in 3 patients (2 in
group 1 and 1 in group 2), while total RD was seen in 6 pa-
tients (2 in group 1 and 4 in group 2) at the end of 6 months
follow-up (Fig. 3). One patient in group 1 who had developed
bleeding and non resolving hyphema in the anterior cham-
ber, started to develop phthisical changes at the end of firstmonth. Another patient in group 1 had raised IOP and re-
quired trabeculectomy followed by a repeat vitrectomy.
Overall, recurrence of proliferation was seen in 20 (50%) pa-
tients (45% in group I and 55% in group II). Out of these 20
patients 13 (32.5%) patients needed repeat surgery due to
recurrence of PVR within three months (6 in group 1 and 7
in group 2). Final visual outcomes in both groups at the
end of 6 months are shown in Table 3.
Discussion
Our study, initially showed no difference in disease sever-
ity, evidenced by average Asaria scores of group 1 = 8.68
and group 2 = 9.13. Asaria and colleagues have found the
chosen criteria to be significantly predictive of developing
PVR,19 in order of importance: aphakia, pre-operative PVR,
size of detachment, anterior uveitis, previous cryotherapy,
and vitreous hemorrhage. Most other studies have also se-
lected either patients with existing PVR or patients from a
mixed cohort. Blankenship used a single 10 mg dose of
5FU at the end of surgery in a prospective randomized trial
in patients with severe PVR.24 The dose was well tolerated
clinically, but prolonged corneal edema was observed as a
side effect. In our study with low-dose 5 FU, no corneal com-
plications were seen.
Blumenkranz et al.18 injected 5FU either intravitreally or
subconjunctivally in 22 patients with severe PVR. They found
a reattachment rate of 60% with minimal side effects, consis-
tent with the results of our study. Asaria et al. in a random-
ized, double blind, controlled study of 174 patients, found
a significant reduction in the incidence of postoperative
PVR, as well as a reduction in the number of reoperations
resulting from PVR, in patients receiving 5FU and LMWH
(postoperative PVR 26.4% in the placebo group and 12.6%
in the 5FU and LMWH group).21 In contrast, our study did
not find any statistically significant difference between treat-
ment and control groups.
At the six-month follow-up of our study, use of the Chi-
square test showed retinal reattachment of x2 = 0.106,
P > 0.05, failing to show a statistically significant difference
between the two groups. The rate of postoperative PVR was
55% (11 patients) in group 2 and 45% (9 patients) in group 1.
The Chi-square test analysis gave a significance value of
x2 = 0.4, P > 0.05, which is not statistically significant. This ef-
fect is seen in the rate of reoperations and the underlying
Figure 3. Retinal reattachment rates seen in study and control groups (ON-on retina, PO-retina partially off, TO-total off).
Table 3. Visual outcome at the end of 6 months in study (group 1) and
control (group 2) groups.
Visual acuity Group 1 Group 2
<CF close to face 9 (45%) 7 (35%)
20/8000–20/2666 3 (15%) 1 (5%)
20/800–20/400 7 (35%) 3 (15%)
20/400–P20/200 2 (10%) 3 (15%)
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eration causing recurrent RD or dry folds.
Considering visual outcome, 45% of cases (9 patients) in
the group 1 and 30% of cases (6 patients) in the group 2
had visual acuity of 20/800 or better. Analysis of the number
of patients recovering some useful vision using the
Chi-square test showed x2 = 0.1002, P > 0.05. Thus, visual
outcome did not show any statistically significant difference
between the two groups either. With the exception of intra-
operative bleeding in 1 patient (5%) from group 1, no other
treatment related complications were found. No drug toxic-
ity was seen clinically in the short follow-up, although these
patients will be monitored with a high index of suspicion.
All patients recruited for the study exhibited a poor visual
prognosis with high Asaria scores. While no single surgical
procedure can effectively manage this severe stage of the
disease, supplementary adjuvant therapy along with aggres-
sive surgical procedures remains as treatment options.
The beneficial effects of drug treatment could not be
proven with our study; however, this may be due to a small
sample size and brief follow-up period. Given the preponder-
ance of young patients in both groups (mostly between 10
and 25 years old), stability of retinal reattachment is crucial
and follow-up of three months is not sufficient for conclusive
results. Also, one must entertain the possibility that imper-
ceptible adverse effects of the adjuvant therapy itself might
annul its favorable actions.
In conclusion, our study fails to prove the efficacy of intra-
operative use of antiproliferative drugs in the prevention of
postoperative PVR or improvement in final visual acuity.
However, no significant treatment-related complications
could be attributed to this treatment. And as shown by theprevious literature, these antiproliferative drugs have been
found to be effective in the prevention of postoperative
proliferation in many experimental, as well as clinical, studies.
Although our study demonstrated negative results, further
investigation is required and a larger definitive trial is
warranted to confirm this study.Financial support
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